Todd Hagopian: Featured in Over 100 Podcasts and Dozens of Authoritative Publications Worldwide

Independent Researcher

Todd Hagopian is an SSRN-published researcher focusing on business transformation, organizational stagnation, and operational turnaround methodologies. His research bridges Fortune 500 practitioner experience with academic frameworks for systematic corporate transformation.

Academic Profiles

• Google Scholar Profile — Research publications and citations
• ORCID Profile — Verified researcher identity (0009-0002-7615-5482)
• SSRN Author Page — Academic working papers and research

Published Research

• The Karelin Method and Rapid Decision-Making: A Framework for Sustainable High-Performance in Manufacturing Organizations (2025) — SSRN Working Paper

Major Media Features & Publications

Forbes.com – Over 30 Featured Articles

Todd Hagopian has been featured on Forbes.com more than 30 times, establishing him as a leading voice in biotechnology investing and business strategy:

• Cannabis Is Todd Hagopian’s Top Biotech Sub-Sector
• Todd Hagopian’s Top Recommendations For 2017
• Biotech Stocks Are Soaring, Todd Hagopian Leads The Way
• NASH Is Todd Hagopian’s Top Biotech Sub-Sector For 2017
• Clovis, Incyte And BioMarin Are Todd Hagopian’s Top Takeover Candidates
• Todd Hagopian’s Top Biotech Takeover Targets For 2017
• Todd Hagopian’s Top 2 Mental Health Biotech Stocks
• Intercept Pharmaceuticals Lost 37% Last Week; Top Biotech Manager Sells
• Sanofi And Celgene Are The Latest To Acquire Promising Biotechs
• Opiant Up Nearly 30% On Favorable Zacks Report
• The 2016 Election Was A Tipping Point For Marijuana Stocks
• Rare Diseases: Biotech’s High Risk, Highest Reward Sub-Sector
• After Gilead’s Acquisition Of KITE, Who Gets Gobbled Up Next?
• How To Maximize Biotech Returns Under Donald Trump
• Donald Trump’s Presidency Triggers Big Gains For Biotech Stocks
• How Gilead Can Double In 3 Years
• 3 Hottest Cancer Biotech Acquisition Targets After Medivation
• Six Major Biotech Acquisitions You Could See in 2016 (Part 2)
• FDA Approves Insys Therapeutics’ 2nd Cannabis-Based Drug
• Buy Insys Therapeutics Before Medical Marijuana Reaches A Tipping Point
• 3 Top Managers Up More Than 24% So Far This Year
• The Case For Flexion To Double By Mid-2017
• Six Major Biotech Acquisitions You Could See In 2016 (Part 1)
• Biotech Pullback Makes Bargains Out Of Alexion, Flexion, Clovis, Tesaro And Incyte
• Clovis Up 10% On Double Normal Volume
• Aging Business Jets Fuel Growth At Textron
• The Cannabis-Based Biotech Sector’s Best Buyout Candidates
• Flexion Can Double Now That FDA Has Approved Zilretta
• After Losing Medivation, Who Is Gilead Going After Next?
• Six Major Biotech Acquisitions You Could See In 2016 (Part 3)
• 3 Ways To Ride The Trends Behind Warren Buffett’s $18B Bet On NetJets
• Top Biotech Manager Sells Arena Pharmaceuticals On Today’s Big Gain
• 10 Managers Who Beat The Top Mutual Fund For The Last Decade
• The Biotech Revolution Comes To Fruition For Investors

Seeking Alpha Investment Analysis

• Scared The Market Will Go Down, But Don’t Want To Sell Everything And Miss The Recovery? Here’s What You Do!
• After Pandora’s Steep Drop, An Acquisition Is Almost Inevitable
• How To Play An Uncertain Oil Market With Near-Certain Returns With Halliburton, Baker Hughes
• 3 Small Cap Bakken Oil Companies Who May Not Survive The Oil Price Plunge
• U.S. Shale Will Shrink By 30%: So Double Your Money Today

Elite Daily – Thought Leadership

• Why I’m A Conservative And Support Gay Marriage
• Stay-At-Home Vs. Working Mothers: Is One Job Harder Than The Other?
• 5 Common Misconceptions About The Federal Minimum Wage In The US
• Social Security Is The Biggest Ponzi Scheme Ever Created And It Still Affects This Generation